Hikma Pharmaceuticals (HIK) Rating Increased to Buy at Citigroup
Hikma Pharmaceuticals (LON:HIK) was upgraded by Citigroup to a “buy” rating in a research report issued to clients and investors on Tuesday.
HIK has been the subject of several other research reports. JPMorgan Chase & Co. decreased their price objective on Hikma Pharmaceuticals from GBX 1,800 ($23.52) to GBX 1,700 ($22.21) and set a “neutral” rating for the company in a report on Thursday, March 14th. HSBC increased their price objective on Hikma Pharmaceuticals from GBX 1,225 ($16.01) to GBX 1,350 ($17.64) and gave the company a “reduce” rating in a report on Thursday, March 14th. Jefferies Financial Group upgraded Hikma Pharmaceuticals to a “buy” rating and increased their price objective for the company from GBX 1,643 ($21.47) to GBX 2,000 ($26.13) in a report on Tuesday, November 27th. Peel Hunt decreased their price objective on Hikma Pharmaceuticals from GBX 2,000 ($26.13) to GBX 1,870 ($24.43) and set a “hold” rating for the company in a report on Tuesday, March 12th. Finally, Numis Securities reiterated a “hold” rating and set a GBX 1,730 ($22.61) price objective on shares of Hikma Pharmaceuticals in a report on Wednesday, March 13th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. Hikma Pharmaceuticals has an average rating of “Hold” and an average target price of GBX 1,830 ($23.91).
Shares of HIK opened at GBX 1,647.50 ($21.53) on Tuesday. Hikma Pharmaceuticals has a 12 month low of GBX 1,078 ($14.09) and a 12 month high of GBX 2,089 ($27.30). The company has a quick ratio of 1.17, a current ratio of 1.87 and a debt-to-equity ratio of 37.54. The firm has a market cap of $3.98 billion and a PE ratio of 14.14.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Read More: Using the New Google Finance Tool
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.